JUBILANT INGREVIA

July 22, 2026

**BSE Limited**
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400001

Scrip Code: **543271**

**National Stock Exchange of India Limited**
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai - 400051

Trading Symbol: **JUBLINGREA**

**Subject: Outcome of the Board Meeting held on July 22, 2026**

**Ref: Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations")**

Dear Sir/Madam,

Pursuant to the provisions of Regulation 33 read with Regulation 30 and other applicable provisions of the Listing Regulations, we wish to inform you that the Board of Directors of the Company at their meeting held today i.e. on Wednesday, July 22, 2026, commenced at 11:00 a.m. and concluded at 12:25 p.m., has, *inter-alia,* approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026 (“Financial Results”).

Pursuant to applicable provisions of the Listing Regulations, we enclose the following:

1. A copy of aforesaid Financial Results and
2. Limited Review Report on the Financial Results issued by the Statutory Auditors of the Company

The above-mentioned documents will also be available on the Company’s website www.jubilantingrevia.com

We request you to take the same on record.
Thanking you

Yours faithfully,

**For Jubilant Ingrevia Limited**

Deepanjali Gulati
Digitally signed by Deepanjali Gulati
Date: 2026.07.22 12:29:19 +05'30'

**Deepanjali Gulati**
**Company Secretary & Compliance Officer**
Encl.: as above




**Jubilant Ingrevia Limited**
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : L24299UP2019PLC122657

**Walker Chandiok & Co LLP**
21st Floor, DLF Square
Jacaranda Marg, DLF Phase II
Gurugram- 122002
India

**T** +91 120 485 5999
**F** +91 120 485 5902

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Jubilant Ingrevia Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Jubilant Ingrevia Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended 30 June 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)**

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review report of the other auditor referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We did not review the interim financial information of a subsidiary included in the Statement, whose financial information reflects total revenues of ₹ 659 lakhs, total net profit after tax of ₹ 33 lakhs and total comprehensive income of ₹ 33 lakhs for the quarter ended on 30 June 2026. These interim financial information have been reviewed by other auditor whose review report has been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of the said subsidiary is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

   Our opinion is not modified in respect of this matter with respect to our reliance on the work done by and the report of the other auditor.

6. The Statement also includes the Group's share of net loss after tax of ₹ 3 lakhs, and total comprehensive loss of ₹ 3 lakhs for the quarter ended on 30 June 2026 in respect of an associate, based on their interim financial information, which have not been reviewed by their auditor, and have been furnished to us by the Holding Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this associate, are based solely on such unreviewed interim financial information. According to the information and explanations given to us by the management, this interim financial information are not material to the Group.

   Our opinion is not modified in respect of this matter with respect to our reliance on the financial information certified by the board of directors.

**For Walker Chandiok & Co LLP**
Chartered Accountants
Firm Registration No: 001076N/N500013

Madhu Sudan

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

**Madhu Sudan Malpani**
Partner
Membership No. 517440

UDIN: 26517440CWXEQS5513

Place: Noida
Date: 22 July 2026

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)**

**Annexure 1**

**List of entities included in the Statement**

| S. No | Name | Relationship with the Holding Company |
|---|---|---|
| 1 | Jubilant Infrastructure Limited | Subsidiary |
| 2 | Jubilant Agro Science Limited | Subsidiary |
| 3 | Jubilant Ingrevia (USA) Inc. (formally known as Jubilant Life Science (USA) Inc.) | Subsidiary |
| 4 | Jubilant Life Sciences NV | Subsidiary |
| 5 | Jubilant Ingrevia International Pte. Limited (formally known as Jubilant Life Sciences International Pte. Limited) | Subsidiary |
| 6 | Jubilant Life Sciences (Shanghai) Limited | Subsidiary |
| 7 | Jubilant Ingrevia Employee Welfare Trust | Subsidiary |
| 8 | Remidex Pharma Private Limited | Subsidiary (with effect from 30 March 2026) |
| 9 | Mister Veg Foods Private Limited | Associate |
| 10 | AMP Energy Green Fifteen Private Limited | Associate |
| 11 | O2 Renewable Energy XVIII Private Limited | Associate (with effect from 25 April 2025) |

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

## Jubilant Ingrevia Limited

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)
CIN:L24299UP2019PLC122657
Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubl.com, Tel: +91-5924-267437

### Statement of Consolidated Unaudited Financial Results for the Quarter Ended 30 June 2026

(₹ in Lakhs)

| Sr. No. | Particulars | Quarter Ended | | | Year Ended |
|---|---|---|---|---|---|
| | | 30 June (Unaudited) 2026 | 31 March (Audited) 2026 | 30 June (Unaudited) 2025 | 31 March (Audited) 2026 |
| 1 | **Revenue from operations** | | | | |
| | a) Sales/Income from operations | 128873 | 116605 | 102942 | 434485 |
| | b) Other operating income | 1154 | 1260 | 845 | 4322 |
| | **Total revenue from operations** | **130027** | **117865** | **103787** | **438807** |
| 2 | Other income | 1022 | 931 | 1130 | 4053 |
| 3 | **Total income (1+2)** | **131049** | **118796** | **104917** | **442860** |
| 4 | **Expenses** | | | | |
| | a) Cost of materials consumed | 71768 | 59738 | 44891 | 210462 |
| | b) Purchases of stock-in-trade | 6405 | 4439 | 3240 | 14904 |
| | c) Changes in inventories of finished goods, stock-in-trade and work-in progress | (15316) | (2301) | 3813 | 4111 |
| | d) Employee benefits expense | 11736 | 10628 | 10823 | 42561 |
| | e) Finance costs | 1743 | 1181 | 1269 | 4912 |
| | f) Depreciation and amortisation expenses | 5101 | 4837 | 4084 | 17548 |
| | g) Other expenses: | | | | |
| | - Power and fuel expense | 13846 | 10824 | 9996 | 41783 |
| | - Others | 21677 | 18277 | 16818 | 68282 |
| | **Total expenses** | **116960** | **107623** | **94934** | **404563** |
| 5 | **Profit before share of profit/(loss) of an associate and exceptional items (3-4)** | **14089** | **11173** | **9983** | **38297** |
| 6 | Share of loss of an associate | (3) | (2) | (6) | (18) |
| 7 | **Profit before exceptional items and tax (5+6)** | **14086** | **11171** | **9977** | **38279** |
| 8 | Exceptional items (refer note 6) | - | - | - | (1304) |
| 9 | **Profit before tax (7+8)** | **14086** | **11171** | **9977** | **36975** |
| 10 | **Tax expense** | | | | |
| | - Current tax | 4296 | 2748 | 2317 | 8423 |
| | - Deferred tax (credit)/charge | (792) | (221) | 150 | 761 |
| 11 | **Net profit for the period/year (9-10)** | **10582** | **8644** | **7510** | **27791** |
| 12 | **Other comprehensive income (OCI)** | | | | |
| | i) a) Items that will not be reclassified to profit or loss | 274 | (391) | 160 | 87 |
| | b) Income tax relating to items that will not be reclassified to profit or loss | (41) | 54 | (16) | (13) |
| | ii) a) Items that will be reclassified to profit or loss | 176 | 736 | 1179 | 2617 |
| | b) Income tax relating to items that will be reclassified to profit or loss | 97 | (185) | (316) | (659) |
| 13 | **Total comprehensive income for the period/year (11+12)** | **11088** | **8858** | **8517** | **29823** |
| | **Net profit attributable to:** | | | | |
| | Owners of the Company | 10582 | 8644 | 7510 | 27791 |
| | Non-controlling interests | - | - | - | - |
| | **Other comprehensive income attributable to:** | | | | |
| | Owners of the Company | 506 | 214 | 1007 | 2032 |
| | Non-controlling interests | - | - | - | - |
| | **Total comprehensive income attributable to:** | | | | |
| | Owners of the Company | 11088 | 8858 | 8517 | 29823 |
| | Non-controlling interests | - | - | - | - |
| 14 | Earnings per share of ₹ 1 each (not annualised for the quarters) | | | | |
| | Basic (₹) | 6.70 | 5.47 | 4.75 | 17.59 |
| | Diluted (₹) | 6.68 | 5.39 | 4.75 | 17.51 |
| 15 | Paid-up equity share capital (face value per share ₹ 1) | 1577 | 1577 | 1581 | 1577 |
| 16 | Reserves excluding revaluation reserves (other equity) | | | | 311045 |
| | **See accompanying notes to the Consolidated Unaudited Financial Results** | | | | |

Jubilant Ingrevia Limited Noida

SIGNED FOR IDENTIFICATION PURPOSES

Walker Chandiok & Co LLP Chartered Accountants

Jubilant Ingrevia Limited

Note 1: Consolidated Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter Ended 30 June 2026

(₹ in Lakhs)

| Sr. No. | Particulars | Quarter Ended | | | Year Ended |
|---|---|---|---|---|---|
| | | 30 June | 31 March | 30 June | 31 March |
| | | (Unaudited) | (Audited) | (Unaudited) | (Audited) |
| | | 2026 | 2026 | 2025 | 2026 |
| 1 | Segment revenue | | | | |
| | a. Speciality Chemicals | 63700 | 60367 | 53697 | 221426 |
| | b. Nutrition & Health Solutions | 24382 | 23028 | 17887 | 79040 |
| | c. Chemical Intermediates | 52517 | 43452 | 38157 | 166798 |
| | Total | **140599** | **126847** | **109741** | **467264** |
| | Less : Inter segment revenue | 10572 | 8982 | 5954 | 28457 |
| | **Total revenue from operations** | **130027** | **117865** | **103787** | **438807** |
| | a. Speciality Chemicals | 53274 | 51590 | 47831 | 193650 |
| | b. Nutrition & Health Solutions | 24346 | 22996 | 17869 | 78970 |
| | c. Chemical Intermediates | 52407 | 43279 | 38087 | 166187 |
| | Total | **130027** | **117865** | **103787** | **438807** |
| 2 | **Segment results (profit before tax and interest)** | | | | |
| | a. Speciality Chemicals | 10914 | 11293 | 10623 | 41038 |
| | b. Nutrition & Health Solutions | 2826 | 2579 | 1999 | 7942 |
| | c. Chemical Intermediates | 4397 | 551 | 497 | 1891 |
| | Total | **18137** | **14423** | **13119** | **50871** |
| | Less: i. Interest (finance costs) | 1743 | 1181 | 1269 | 4912 |
| | ii. Un-allocable expenditure (net of un-allocable income) | 2308 | 2071 | 1873 | 7680 |
| | iii. Exceptional Item - One Time impact of New Labour Codes | - | - | - | 1304 |
| | **Profit before tax** | **14086** | **11171** | **9977** | **36975** |
| 3 | **Segment assets** | | | | |
| | a. Speciality Chemicals | 317063 | 295402 | 288056 | 295402 |
| | b. Nutrition & Health Solutions | 90131 | 80308 | 79418 | 80308 |
| | c. Chemical Intermediates | 157139 | 143884 | 147607 | 143884 |
| | d. Unallocable corporate assets | 33298 | 28779 | 22746 | 28779 |
| | **Total segment assets** | **597631** | **548373** | **537827** | **548373** |
| 4 | **Segment liabilities** | | | | |
| | a. Speciality Chemicals | 73622 | 64627 | 61226 | 64627 |
| | b. Nutrition & Health Solutions | 16853 | 14686 | 15770 | 14686 |
| | c. Chemical Intermediates | 60535 | 53017 | 49953 | 53017 |
| | d. Unallocable corporate liabilities | 122476 | 103421 | 109377 | 103421 |
| | **Total segment liabilities** | **273486** | **235751** | **236326** | **235751** |

Jubilant Ingrevia Limited Noida

SIGNED FOR IDENTIFICATION PURPOSES

WALKER CHANDIOK & CO LLP CHARTERED ACCOUNTANTS

# Jubilant Ingrevia Limited

Note 2: Additional disclosure as per Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

(Consolidated)

| Sr. No. | Particulars | Quarter Ended | | | Year Ended |
|---|---|---|---|---|---|
| | | 30 June (Unaudited) 2026 | 31 March (Audited) 2026 | 30 June (Unaudited) 2025 | 31 March (Audited) 2026 |
| 1 | **Debt service coverage ratio (in times) #**<br>*Definition: EBITDA/{finance costs + scheduled principal repayments (excluding prepayments) during the period for long-term debts}*<br>*{EBITDA: Profit before tax + depreciation and amortisation expense + finance costs}* | 4.81 | 4.68 | 4.72 | 4.39 |
| 2 | **Interest service coverage ratio (in times)**<br>*Definition: EBITDA/finance costs* | 12.01 | 14.55 | 12.08 | 12.36 |
| 3 | **Bad debts to account receivable ratio (%) #**<br>*Definition: Bad debts/average of opening and closing trade receivables*<br>*{Bad debts: Impairment balance as per statements of profit and loss}* | 0.02% | 0.03% | 0.02% | 0.11% |
| 4 | **Debtors turnover (in times) #**<br>*Definition: Revenue from operations/average of opening and closing trade receivables* | 1.52 | 1.60 | 1.60 | 6.32 |
| 5 | **Inventory turnover (in times) #**<br>*Definition: Cost of goods sold/average of opening and closing inventories* | 0.64 | 0.72 | 0.53 | 2.52 |
| 6 | **Operating margin (%)**<br>*Definition: Operating profit/revenue from operations*<br>*{Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - depreciation and amortisation expense - other expenses}*<br>*{Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finished goods, stock-in-trade and work-in-progress}* | 11.39% | 9.69% | 9.76% | 8.92% |
| 7 | **Net profit margin (%)**<br>*Definition: Net profit/total income* | 8.07% | 7.28% | 7.16% | 6.28% |
| 8 | **Net worth (In ₹ Lakhs)**<br>{Net worth: Equity share capital + other equity} | 324145 | 312622 | 301501 | 312622 |
| 9 | **Debt equity ratio (in times)**<br>*Definition: Net debts/net worth*<br>*{Net debts: Long term borrowings (gross of transaction costs) + short term borrowings - cash and cash equivalents - other bank balances}* | 0.22 | 0.19 | 0.23 | 0.19 |
| 10 | **Current ratio (in times)**<br>*Definition: Current assets/current liabilities* | 1.24 | 1.29 | 1.28 | 1.29 |
| 11 | **Long term debt to working capital (in times)**<br>*Definition: Long term debt/working capital*<br>*{Long term debt: Long term borrowings (gross of transaction costs)}*<br>*{working capital: Current assets - current liabilities}* | 0.59 | 0.71 | 0.98 | 0.71 |
| 12 | **Current liability ratio (in times)**<br>*Definition: Current liabilities/total liabilities* | 0.74 | 0.68 | 0.69 | 0.68 |
| 13 | **Total debts to total assets (in times)**<br>*Definition: Total debts/total assets*<br>*{Total debts: Long term borrowings (gross of transaction costs + short term borrowings)}* | 0.15 | 0.14 | 0.15 | 0.14 |

# not annualised for the quarters

Jubilant Ingrevia Limited Noida

SIGNED FOR IDENTIFICATION PURPOSES

Walker Chandiok & Co LLP Chartered Accountants

**Notes to consolidated audited financial results (cont'd):**

3. These consolidated unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

4. The Group comprises of the following components:

| Name | Relationship with the Holding Company |
|---|---|
| Jubilant Infrastructure Limited | Subsidiary |
| Jubilant Agro Science Limited | Subsidiary |
| Jubilant Ingrevia (USA) Inc.<br>(formally known as Jubilant Life Science (USA) Inc.) | Subsidiary |
| Jubilant Life Sciences NV | Subsidiary |
| Jubilant Ingrevia International Pte. Limited<br>(formally known as Jubilant Life Sciences International Pte. Limited) | Subsidiary |
| Jubilant Life Sciences (Shanghai) Limited | Subsidiary |
| Jubilant Ingrevia Employee Welfare Trust | Subsidiary |
| Remidex Pharma Private Limited | Subsidiary (with effect from 30 March 2026) |
| Mister Veg Foods Private Limited | Associate |
| AMP Energy Green Fifteen Private Limited | Associate |
| O2 Renewable Energy XVIII Private Limited | Associate (with effect from 25 April 2025) |

5. During the quarter ended 30 June 2026, the Holding Company has granted 343569 stock options to the eligible employees as determined by the Nomination, Remuneration and Compensation Committee of the Holding Company.

6. During the previous year, effective 21 November 2025, the Government of India has consolidated multiple existing labour legislations into a unified framework comprising of four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020, collectively referred to as the 'New Labour Codes'. The enactment of these codes has resulted in changes to the computation of certain employee benefits primarily due to change in definition of 'wages' under these Codes. Based on the currently available information, the Group has assessed the impact of these changes in accordance with Ind AS 19 – Employee Benefits and the guidance issued by the Institute of Chartered Accountants of India (ICAI). The resulting additional employee benefit expense of ₹ 1304 lakhs, being material and non-recurring, has been presented under "Exceptional Items" in the financial results for the year ended 31 March 2026. During the quarter, on 08 May 2026, the Central Government notified the Code of Wages (Central) Rules, 2026 and the Group is currently evaluating the consequential impact of these Rules. The Group continues to monitor developments pertaining to the Labour Codes and would provide appropriate accounting impact on the basis of such developments as needed.

7. The figures for the quarter ended 31 March 2026, as reported in consolidated financial results, are balancing figures between the audited figures for the year ended 31 March 2026 and the published year to date figures for 31 December 2025, which were subject to limited review by the statutory auditors.

8. Previous periods figures have been regrouped/reclassified, wherever necessary. The impact of such reclassification/regrouping is not material to the financial results.

9. The above consolidated unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 22 July 2026. The limited review report of the Statutory Auditors is being filed with the BSE Limited and the National Stock Exchange Limited of India. For more details on consolidated unaudited results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

For Jubilant Ingrevia Limited

Deepak Jain
CEO & Managing Director

Place : Noida
Date : 22 July 2026

Jubilant Ingrevia Limited Noida

SIGNED FOR IDENTIFICATION PURPOSES

WALKER CHANDIOK & CO LLP CHARTERED ACCOUNTANTS

**Walker Chandiok & Co LLP**
21st Floor, DLF Square
Jacaranda Marg, DLF Phase II
Gurugram- 122002
India

T +91 120 485 5999
F +91 120 485 5902

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Jubilant Ingrevia Limited**

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Jubilant Ingrevia Limited ('the Company') for the quarter ended 30 June 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd)**

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Walker Chandiok & Co LLP**
Chartered Accountants
Firm Registration No: 001076N/N500013

Madhu Sudan

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

**Madhu Sudan Malpani**
Partner
Membership No. 517440

**UDIN:** 26517440LGYEAT2023

**Place:** Noida
**Date:** 22 July 2026

## Jubilant Ingrevia Limited

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubl.com, Tel: +91-5924-267437

Statement of Standalone Unaudited Financial Results for the Quarter Ended 30 June 2026

| Sr. No. | Particulars | Quarter Ended | | | Year Ended |
|---|---|---|---|---|---|
| | | 30 June (Unaudited) 2026 | 31 March (Audited) 2026 | 30 June (Unaudited) 2025 | 31 March (Audited) 2026 |
| 1 | **Revenue from operations** | | | | |
| | a) Sales/Income from operations | 124233 | 108131 | 96455 | 409745 |
| | b) Other operating income | 1032 | 1216 | 845 | 4104 |
| | **Total revenue from operations** | **125265** | **109347** | **97300** | **413849** |
| 2 | Other income | 1057 | 4603 | 1118 | 9969 |
| 3 | **Total income (1+2)** | **126322** | **113950** | **98418** | **423818** |
| 4 | **Expenses** | | | | |
| | a) Cost of materials consumed | 71370 | 59722 | 47549 | 215457 |
| | b) Purchases of stock-in-trade | 5150 | 2856 | 3240 | 12288 |
| | c) Changes in inventories of finished goods, stock-in-trade and work-in-progress | (11765) | (2933) | 2412 | 2104 |
| | d) Employee benefits expense | 9760 | 9179 | 9661 | 37295 |
| | e) Finance costs | 1430 | 1314 | 1483 | 5662 |
| | f) Depreciation and amortisation expenses | 4052 | 4284 | 3823 | 16118 |
| | g) Other expenses: | | | | |
| | - Power and fuel expense | 13618 | 11804 | 10390 | 44321 |
| | - Others | 15746 | 14948 | 11918 | 55145 |
| | **Total expenses** | **109361** | **101174** | **90476** | **388390** |
| 5 | **Profit before exceptional items and tax (3-4)** | **16961** | **12776** | **7942** | **35428** |
| 6 | Exceptional items (refer note 5) | - | - | - | (1222) |
| 7 | **Profit before tax (5+6)** | **16961** | **12776** | **7942** | **34206** |
| 8 | **Tax expense** | | | | |
| | - Current tax | 3959 | 2189 | 1667 | 6627 |
| | - Deferred tax charge | 380 | 65 | 374 | 782 |
| 9 | **Net profit for the period/year (7-8)** | **12622** | **10522** | **5901** | **26797** |
| 10 | **Other comprehensive income (OCI)** | | | | |
| | i) a) Items that will not be reclassified to profit or loss | 5 | 33 | (70) | 20 |
| | b) Income tax relating to items that will not be reclassified to profit or loss | (1) | (8) | 18 | (5) |
| | ii) a) Items that will be reclassified to profit or loss | - | - | - | - |
| | b) Income tax relating to items that will be reclassified to profit or loss | - | - | - | - |
| 11 | **Total comprehensive income for the period/year (9+10)** | **12626** | **10547** | **5849** | **26812** |
| 12 | Earnings per share of ₹ 1 each (not annualised for the quarters) | | | | |
| | Basic (₹) | 7.92 | 6.60 | 3.70 | 16.82 |
| | Diluted (₹) | 7.92 | 6.60 | 3.70 | 16.82 |
| 13 | Paid-up equity share capital (face value per share ₹ 1) | 1593 | 1593 | 1593 | 1593 |
| 14 | Reserves excluding revaluation reserves (other equity) | | | | 262413 |
| | **See accompanying notes to the Standalone Unaudited Financial Results** | | | | |

Jubilant Ingrevia Limited Noida

SIGNED FOR IDENTIFICATION PURPOSES

WALKER CHANDIOK & CO LLP CHARTERED ACCOUNTANTS

# Jubilant Ingrevia Limited

Note 1: Standalone Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter Ended 30 June 2026

(₹ in Lakhs)

| Sr. No. | Particulars | Quarter Ended | | | Year Ended |
|---|---|---|---|---|---|
| | | 30 June | 31 March | 30 June | 31 March |
| | | (Unaudited) | (Audited) | (Unaudited) | (Audited) |
| | | 2026 | 2026 | 2025 | 2026 |
| 1 | **Segment revenue** | | | | |
| | a. Speciality Chemicals | 56853 | 57529 | 51063 | 213992 |
| | b. Nutrition & Health Solutions | 22457 | 19396 | 16401 | 72261 |
| | c. Chemical Intermediates | 56527 | 41404 | 35790 | 156053 |
| | **Total** | **135837** | **118329** | **103254** | **442306** |
| | Less : Inter segment revenue | 10572 | 8982 | 5954 | 28457 |
| | **Total revenue from operations** | **125265** | **109347** | **97300** | **413849** |
| | a. Speciality Chemicals | 46428 | 48752 | 45197 | 186216 |
| | b. Nutrition & Health Solutions | 22421 | 19364 | 16383 | 72191 |
| | c. Chemical Intermediates | 56416 | 41231 | 35720 | 155442 |
| | **Total** | **125265** | **109347** | **97300** | **413849** |
| 2 | **Segment results (profit before tax and interest)** | | | | |
| | a. Speciality Chemicals | 10169 | 15398 | 10742 | 47789 |
| | b. Nutrition & Health Solutions | 1965 | 864 | 357 | 3037 |
| | c. Chemical Intermediates | 8452 | (155) | 189 | (2173) |
| | **Total** | **20586** | **16107** | **11288** | **48653** |
| | Less: i. Interest (finance costs) | 1430 | 1314 | 1483 | 5662 |
| | ii. Un-allocable expenditure (net of un-allocable income) | 2195 | 2017 | 1863 | 7563 |
| | iii. Exceptional Item - One Time impact of New Labour Codes | - | - | - | 1222 |
| | **Profit before tax** | **16961** | **12776** | **7942** | **34206** |
| 3 | **Segment assets** | | | | |
| | a. Speciality Chemicals | 249260 | 232316 | 241328 | 232316 |
| | b. Nutrition & Health Solutions | 71523 | 61493 | 57638 | 61493 |
| | c. Chemical Intermediates | 140850 | 124896 | 129536 | 124896 |
| | d. Unallocable corporate assets | 55111 | 53625 | 44977 | 53625 |
| | **Total segment assets** | **516744** | **472330** | **473479** | **472330** |
| 4 | **Segment liabilities** | | | | |
| | a. Speciality Chemicals | 52471 | 42659 | 47529 | 42659 |
| | b. Nutrition & Health Solutions | 15656 | 15300 | 13197 | 15300 |
| | c. Chemical Intermediates | 59931 | 55025 | 52626 | 55025 |
| | d. Unallocable corporate liabilities | 111619 | 95340 | 109915 | 95340 |
| | **Total segment liabilities** | **239677** | **208324** | **223267** | **208324** |

Jubilant Ingrevia Limited Noida

SIGNED FOR IDENTIFICATION PURPOSES

WALKER CHANDIOK & CO LLP

# Jubilant Ingrevia Limited

**Note 2: Additional disclosure as per Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

(Standalone)

| Sr. No. | Particulars | Quarter Ended | | | Year Ended |
|---|---|---|---|---|---|
| | | 30 June (Unaudited) 2026 | 31 March (Audited) 2026 | 30 June (Unaudited) 2025 | 31 March (Audited) 2026 |
| 1 | **Debt service coverage ratio (in times)#**<br>*Definition: EBITDA/{finance costs + scheduled principal repayments (excluding prepayments) during the period for long-term debts}*<br>*{EBITDA: Profit before tax + depreciation and amortisation expense + finance costs}* | 5.83 | 5.08 | 4.05 | 4.13 |
| 2 | **Interest service coverage ratio (in times)**<br>*Definition: EBITDA/finance costs* | 15.69 | 13.98 | 8.93 | 10.10 |
| 3 | **Bad debts to account receivable ratio (%)#**<br>*Definition: Bad debts/average of opening and closing trade receivables*<br>*{Bad debts: Impairment balance as per statements of profit and loss}* | 0.03% | 0.03% | 0.02% | 0.12% |
| 4 | **Debtors turnover (in times)#**<br>*Definition: Revenue from operations/average of opening and closing trade receivables* | 1.67 | 1.65 | 1.62 | 6.56 |
| 5 | **Inventory turnover (in times)#**<br>*Definition: Cost of goods sold/average of opening and closing inventories* | 0.79 | 0.84 | 0.63 | 2.99 |
| 6 | **Operating margin (%)**<br>*Definition: Operating profit/revenue from operations*<br>*{Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - depreciation and amortisation expense - other expenses}*<br>*{Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finished goods, stock-in-trade and work-in-progress}* | 13.84% | 8.68% | 8.55% | 7.52% |
| 7 | **Net profit margin (%)**<br>*Definition: Net profit/total income* | 9.99% | 9.24% | 5.99% | 6.32% |
| 8 | **Net worth (In ₹ Lakhs)**<br>*{Net worth: Equity share capital + other equity}* | 277067 | 264006 | 250212 | 264006 |
| 9 | **Debt equity ratio (in times)**<br>*Definition: Net debts/net worth*<br>*{Net debts: Long term borrowings (gross of transaction costs) + short term borrowings - cash and cash equivalents - other bank balances}* | 0.23 | 0.20 | 0.30 | 0.20 |
| 10 | **Current ratio (in times)**<br>*Definition: Current assets/current liabilities* | 1.17 | 1.18 | 1.16 | 1.18 |
| 11 | **Long term debt to working capital (in times)**<br>*Definition: Long term debt/working capital*<br>*{Long term debt: Long term borrowings (gross of transaction costs)}*<br>*{working capital: Current assets - current liabilities}* | 0.60 | 0.80 | 1.66 | 0.80 |
| 12 | **Current liability ratio (in times)**<br>*Definition: Current liabilities/total liabilities* | 0.78 | 0.73 | 0.71 | 0.73 |
| 13 | **Total debts to total assets (in times)**<br>*Definition: Total debts/total assets*<br>*{Total debts: Long term borrowings (gross of transaction costs) + short term borrowings}* | 0.16 | 0.15 | 0.17 | 0.15 |

# not annualised for the quarters

Jubilant Ingrevia Limited Noida

SIGNED FOR IDENTIFICATION PURPOSES

Walker Chandiok & Co LLP Chartered Accountants

**Notes to standalone audited financial results (cont'd):**

3. These standalone unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

4. During the quarter ended 30 June 2026, the Company has granted 343569 stock options to the eligible employees as determined by the Nomination, Remuneration and Compensation Committee of the Company.

5. During the previous year, effective 21 November 2025, the Government of India has consolidated multiple existing labour legislations into a unified framework comprising of four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020, collectively referred to as the 'New Labour Codes'. The enactment of these codes has resulted in changes to the computation of certain employee benefits primarily due to change in definition of 'wages' under these Codes. Based on the currently available information, the Company has assessed the impact of these changes in accordance with Ind AS 19 – Employee Benefits and the guidance issued by the Institute of Chartered Accountants of India (ICAI). The resulting additional employee benefits expense of ₹ 1222 lakhs, being material and non-recurring, has been presented under "Exceptional Items" in the financial results for the year ended 31 March 2026. During the quarter, on 08 May 2026, the Central Government notified the Code of Wages (Central) Rules, 2026 and the Company is currently evaluating the consequential impact of these Rules. The Company continues to monitor developments pertaining to the Labour Codes and would provide appropriate accounting impact on the basis of such developments as needed.

6. The figures for the quarter ended 31 March 2026, as reported in standalone financial results, are balancing figures between the audited figures for the year ended 31 March 2026 and the published year to date figures for 31 December 2025, which were subject to limited review by the statutory auditors.

7. Previous periods figures have been regrouped/reclassified, wherever necessary. The impact of such reclassification/regrouping is not material to the financial results.

8. The above standalone unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 22 July 2026. The limited review report of the Statutory Auditors is being filed with the BSE Limited and the National Stock Exchange Limited of India. For more details on standalone unaudited results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

For Jubilant Ingrevia Limited

Deepak Jain
CEO & Managing Director

Place : Noida
Date : 22 July 2026

Jubilant Ingrevia Limited Noida ★

SIGNED FOR IDENTIFICATION PURPOSES

WALKER CHANDIOK & CO LLP CHARTERED ACCOUNTANTS